AFMDQ (Affimed NV) Cyclically Adjusted Revenue per Share: $3.00 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AFMDQ Affimed NV AFMDQ
16 GF Score
Price $0.00
View Full Analysis

What is Affimed NV Cyclically Adjusted Revenue per Share?

Affimed NV AFMDQ 16 Cyclically Adjusted Revenue per Share is $3.00 as of Sep. 2024. GuruFocus rates AFMDQ with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Affimed NV's adjusted revenue per share for the three months ended in Sep. 2024 was $0.011. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.00 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-30), Affimed NV's current stock price is $0.0001. Affimed NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $3.00. Affimed NV's Cyclically Adjusted PS Ratio of today is 0.00.


Affimed NV  (OTCPK:AFMDQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Affimed NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.0001/3.00
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Affimed NV Cyclically Adjusted Revenue per Share Related Terms


Affimed NV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Affimed NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV Cyclically Adjusted Revenue per Share Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.34 3.17

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 3.17 3.15 3.12 3.00

AFMDQ vs SYRS, BTAX, TRVN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Affimed NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's Cyclically Adjusted PS Ratio falls into.


AFMDQ
16GF Score
Affimed NV AFMDQ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Affimed NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Affimed NV's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.011/126.1978*126.1978
=0.011

Current CPI (Sep. 2024) = 126.1978.

Affimed NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.042 99.543 0.053
201503 1.111 99.717 1.406
201506 0.909 100.417 1.142
201509 0.427 100.417 0.537
201512 0.542 99.717 0.686
201603 0.637 100.017 0.804
201606 0.694 100.717 0.870
201609 0.317 101.017 0.396
201612 0.428 101.217 0.534
201703 0.105 101.417 0.131
201706 0.129 102.117 0.159
201709 0.124 102.717 0.152
201712 0.167 102.617 0.205
201803 0.120 102.917 0.147
201806 0.028 104.017 0.034
201809 0.057 104.718 0.069
201812 4.145 104.217 5.019
201903 2.055 104.217 2.488
201906 0.725 105.718 0.865
201909 0.371 106.018 0.442
201912 0.572 105.818 0.682
202003 0.744 105.718 0.888
202006 0.417 106.618 0.494
202009 1.444 105.818 1.722
202012 1.283 105.518 1.534
202103 1.194 107.518 1.401
202106 0.977 108.486 1.137
202109 0.851 109.435 0.981
202112 0.955 110.384 1.092
202203 0.714 113.968 0.791
202206 0.524 115.760 0.571
202209 0.987 118.818 1.048
202212 0.791 119.345 0.836
202303 0.323 122.402 0.333
202306 0.101 123.140 0.104
202309 0.140 124.195 0.142
202312 0.030 123.773 0.031
202403 0.011 125.038 0.011
202406 0.011 125.882 0.011
202409 0.011 126.198 0.011

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $3.00 mean?
Affimed NV (AFMDQ) has a Cyclically Adjusted Revenue per Share of $3.00 as of Sep. 2024. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Affimed NV and its competitors.
Is Affimed NV's Cyclically Adjusted Revenue per Share too high?
Affimed NV's current Cyclically Adjusted Revenue per Share is $3.00. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's Cyclically Adjusted Revenue per Share compare to SYRS and BTAX?
Affimed NV's Cyclically Adjusted Revenue per Share of $3.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Affimed NV and its competitors. Affimed NV's current Cyclically Adjusted Revenue per Share is $3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current Cyclically Adjusted Revenue per Share of $3.00. The current Cyclically Adjusted Revenue per Share is $3.00. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current Cyclically Adjusted Revenue per Share is $3.00 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Affimed NV Business Description

Address Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score

Get the complete analysis for AFMDQ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price